KYTH-105 FDA Approval Status
FDA Approved: No
Brand name: KYTH-105
Generic name: setipiprant
Company: Kythera Biopharmaceuticals, Inc.
Treatment for: Androgenetic Alopecia
KYTH-105 (setipiprant) is an oral prostaglandin D2 (PGD2) receptor antagonist in development for the treatment of androgenetic alopecia (AGA), or male pattern hair loss.
Development timeline for KYTH-105
|Sep 22, 2015||Kythera Biopharmaceuticals Submits Investigational New Drug Application for KYTH-105 to Treat Androgenetic Alopecia|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.